HAIP Chemotherapy or Resection for Multifocal Bile Duct Cancer?
(MedPage Today) -- Hepatic arterial infusion pump (HAIP) floxuridine chemotherapy may represent an effective alternative to curative-intent resection in patients with multifocal intrahepatic cholangiocarcinoma who are at risk for surgical complications... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - May 11, 2022 Category: Surgery Source Type: news

U.S. Food and Drug Administration (FDA) Accepts for Priority Review Taiho Oncology ’s New Drug Application for Futibatinib for Cholangiocarcinoma
PRINCETON, N.J., MARCH 30, 2022– Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for futibatinib in the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 30, 2022 Category: Drugs & Pharmacology Source Type: news

KRAS-Variant Subtypes Tied to Worse Outcomes in Intrahepatic Bile Duct Cancer KRAS-Variant Subtypes Tied to Worse Outcomes in Intrahepatic Bile Duct Cancer
In patients with intrahepatic cholangiocarcinoma who underwent curative resection, G12 KRAS variants, were associated with worse survival and increased risk of recurrence in a Chinese cohort study.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 19, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

Consumer Health: What do you know about liver cancer?
October is Liver Cancer Awareness Month, which makes this a good time to learn more about liver cancer. More than 42,000 new cases of primary liver cancer and intrahepatic bile duct cancer will be diagnosed in the U.S. this year, and more than 30,000 people will die of these diseases, according to the American Cancer Society. Liver cancer is cancer that begins in the cells of your liver, which is a football-sized organ in the upper… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 7, 2021 Category: Databases & Libraries Source Type: news

Pharma built on Shire's old cancer business gets new FDA approval
Servier Pharmaceuticals, the Boston-based subsidiary of the French Servier Group that was built around Shire plc ’s cancer business, has scored an approval from the U.S. Food and Drug Administration for a cancer drug and a related diagnostic test. The FDA on Wednesday gave the go-ahead to a drug called Tibsovo, which is currently only used to treat a specific type of acute myeloid leukemia, to be used in a mutation-specific metastatic cholangiocarcinoma, a rare but aggressive cancer that attacks… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 26, 2021 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news

FDA Approves Ivosidenib for Bile Duct Cancer FDA Approves Ivosidenib for Bile Duct Cancer
Ivosidenib is the first targeted therapy approved for the treatment of IDH1-mutated cholangiocarcinomaFDA Approvals (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - August 26, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma
Oncology (Cancer) FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 26, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Servier Announces FDA Approval of Tibsovo (ivosidenib tablets) in IDH1-Mutated Cholangiocarcinoma
Tibsovo is the first and only targeted therapy approved for patients with previously treated IDH1-mutated cholangiocarcinoma BOSTON, Aug. 25, 2021 /PRNewswire/ -- Servier Pharmaceuticals, a growing leader in oncology committed to bringing the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 25, 2021 Category: Drugs & Pharmacology Source Type: news

Complex CAFs
Diversity among cancer-associated fibroblasts from cholangiocarcinomas reveals distinct roles in tumor progression. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - July 6, 2021 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news

TRUSELTIQ (infigratinib), FDA Approved for Treatment of Cholangiocarcinoma, Available at Biologics by McKesson
CARY, N.C., June 21, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by QED Therapeutics, an affiliate of BridgeBio Pharma, Inc. (BridgeBio) and Helsinn Group, as a specialty pharmacy provider for TRUSELTIQTM (infigrati... (Source: McKesson News)
Source: McKesson News - June 21, 2021 Category: Information Technology Source Type: news

Novel Drug Approved by FDA for Some Bile Duct Cancers Novel Drug Approved by FDA for Some Bile Duct Cancers
Infigratinib was approved for use in adults with previously treated unresectable bile duct cancer harboring an FGFR2 fusion or other rearrangement.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 2, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma
Hematology / Oncology (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 28, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Truseltiq (infigratinib) for the Treatment of Cholangiocarcinoma
PALO ALTO, Calif. and LUGANO, Switzerland, May 28, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate QED Therapeutics, Inc., and Helsinn Group today announced that the US Food and Drug Administration (FDA) has... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 28, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Grants Breakthrough Therapy Designation for Taiho Oncology's Futibatinib for Treatment of Advanced Cholangiocarcinoma
PRINCETON, N.J. and TOKYO, April 1, 2021 -- (Healthcare Sales & Marketing Network) -- Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BT... Biopharmaceuticals, Oncology, FDA Taiho Oncology, Taiho Pharmaceutical, futibatinib, cholangiocarcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 1, 2021 Category: Pharmaceuticals Source Type: news

Europe Approves Pemigatinib for Bile Duct Cancer Europe Approves Pemigatinib for Bile Duct Cancer
The oral targeted therapy is for the treatment of locally advanced or metastatic cholangiocarcinoma.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 31, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news